concept

CSF

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about CSF: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

134Connections

30Hypotheses

11Analyses

50Outgoing

50Incoming

1Experiments

15Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	CSF
Key Genes/Proteins	ACSL4, ADAM10, AMYLOID, AMYLOID-BETA, APOE, APP
Related Diseases	AGING, ALS, ALZHEIMER, ALZHEIMER'S DISEASE
Related Pathways	AMPK SIGNALING
Linked Hypotheses	36 hypotheses

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Validated Hypothesis: Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2, and Neurogranin

hypothesis · 3867 words

→

Validated Hypothesis: CSF sTREM2 as Pharmacodynamic Biomarker for Therapeutic Window Identification

hypothesis · 3456 words

→

Cerebrospinal Fluid (CSF) Biomarkers in Neurodegeneration

diagnostic · 3175 words

→

Pathway Diagram

graph TD
    CSF[CSF]
    CSF -->|involved_in| Glymphatic_Pathway[Glymphatic Pathway]
    CSF -->|contains| PD_ProS[PD_ProS]
    CSF -->|activates| AQP4[AQP4]
    CSF -->|inhibits| MELANOMA[MELANOMA]
    CSF -->|regulates| TAU[TAU]
    CSF -->|interacts| SYK[SYK]
    CSF -->|interacts| ALZHEIMER_S_DISEASE[ALZHEIMER'S DISEASE]
    CSF -->|phosphorylates| NEURODEGENERATION[NEURODEGENERATION]
    Cryptic_Hdgfl2[Cryptic Hdgfl2] -->|expressed in| CSF
    TAU -->|expressed in| CSF
    OSTEOCLASTS[OSTEOCLASTS] -->|regulates| CSF
    NGF[NGF] -->|interacts| CSF
    MACROPHAGE[MACROPHAGE] -->|activates| CSF
    neurodegeneration[neurodegeneration] -->|regulates| CSF
    AQP4 -->|loss_affects| CSF
    APOE[APOE] -->|produces| CSF

Outgoing (58)

Target	Relation	Type	Str
h-cef0dd34	targeted_by	hypothesis	1.00
h-var-c261b9d0cd	targeted_by	hypothesis	1.00
h-var-3049fa9ae4	targeted_by	hypothesis	1.00
Glymphatic Pathway	involved_in	pathway	0.90
PD_ProS	contains	phenotype	0.72
MICROGLIA	regulates	cell_type	0.65
MICROGLIAL ACTIVATION	interacts_with	phenotype	0.65
ALZHEIMER	biomarker_for	disease	0.65
ALZHEIMER	phosphorylates	disease	0.65
ALZHEIMER'S DISEASE	interacts_with	disease	0.65
AQP4	activates	gene	0.65
MELANOMA	inhibits	disease	0.65
TAU	regulates	protein	0.65
PARKINSON'S DISEASE	biomarker_for	disease	0.65
SYK	activates	gene	0.65
NEURODEGENERATION	phosphorylates	phenotype	0.65
NEURODEGENERATION	exacerbates	phenotype	0.65
SYK	interacts_with	gene	0.65
PROTEOME	contains	pathway	0.64
MICROGLIAL ACTIVATION	stabilizes	phenotype	0.60
HISTONE ACETYLATION	inhibits	phenotype	0.60
AGING	biomarker_for	phenotype	0.60
PRION	phosphorylates	protein	0.60
MICROGLIAL ACTIVATION	treats	phenotype	0.60
APP	exacerbates	gene	0.60
TAU	targets	protein	0.60
NEUROFILAMENT LIGHT	synergizes_with	biomarker	0.60
NEUROFILAMENT LIGHT	regulates	biomarker	0.60
ATM	activates	gene	0.60
TAU	causes	protein	0.60
TAU	inhibits	protein	0.60
KDM6A	stabilizes	gene	0.60
BDNF	stabilizes	gene	0.60
BDNF	protects_against	gene	0.60
BDNF	activates	gene	0.60
JNK	activates	gene	0.60
TAU	associated_with	protein	0.60
P-TAU	associated_with	protein	0.60
TAU	stabilizes	protein	0.60
TDP-43	phosphorylates	gene	0.60
TDP-43	stabilizes	gene	0.60
TAU	phosphorylates	protein	0.60
APOE	treats	gene	0.60
AUTOPHAGY	activates	phenotype	0.60
AMYLOID	activates	protein	0.60
MITOCHONDRIAL DYSFUNCTION	synergizes_with	phenotype	0.60
AGING	regulates	phenotype	0.60
ADUCANUMAB	interacts_with	drug	0.60
ADUCANUMAB	synergizes_with	drug	0.60
AMYLOID	inhibits	protein	0.60

Incoming (76)

Source	Relation	Type	Str
h-var-c261b9d0cd	targets	hypothesis	1.00
h-var-3049fa9ae4	targets	hypothesis	1.00
h-cef0dd34	targets	hypothesis	1.00
Cryptic Hdgfl2	expressed_in	biomarker	0.92
biomarkers-14-3-3-proteins-csf	describes	wiki	0.90
biomarkers-cbs-psp-csf-biomarkers	describes	wiki	0.90
biomarkers-csf-biomarker-comparison	describes	wiki	0.90
biomarkers-csf-neurofilament-light	describes	wiki	0.90
biomarkers-csf-o-glcnac	describes	wiki	0.90
biomarkers-csf-pta181	describes	wiki	0.90
biomarkers-csf-synaptic-biomarker-panel	describes	wiki	0.90
gaps-csf-cytokine-profiles-pd-biomarkers	describes	wiki	0.90
TAU	expressed_in	protein	0.72
MACROPHAGE	activates	cell_type	0.65
TAU	treats	protein	0.65
TAU	interacts_with	protein	0.65
NGF	interacts_with	gene	0.65
OSTEOCLASTS	regulates	cell_type	0.65
neurodegeneration	regulates	phenotype	0.64
CHOROID PLEXUS	activates	cell_type	0.60
AQP4	loss_affects	entity	0.60
SNAP25	inhibits	gene	0.60
ADAM10	produces	gene	0.60
APOE	produces	gene	0.60
TREM2	stabilizes	gene	0.60
MELATONIN	stabilizes	drug	0.60
ROS	stabilizes	phenotype	0.60
ALS	causes	disease	0.60
ALS	stabilizes	disease	0.60
COGNITIVE DECLINE	stabilizes	phenotype	0.60
COGNITIVE DECLINE	inhibits	phenotype	0.60
ALS	regulates	disease	0.60
34125126	can reflect	paper	0.60
AMYLOID-BETA	produces	protein	0.60
ROS	targets	phenotype	0.60
ASTROCYTE	activates	cell_type	0.60
LRRK2	expressed_in	gene	0.55
BRAF	expressed_in	gene	0.55
MONOCYTES	expressed_in	cell_type	0.55
DASATINIB	associated_with	drug	0.50
COMPLEMENT PATHWAY	associated_with	pathway	0.50
GLIAL FIBRILLARY ACIDIC PROTEIN	associated_with	biomarker	0.50
RIBOSOME	associated_with	organelle	0.50
AMPK SIGNALING	associated_with	pathway	0.50
MOCA	associated_with	biomarker	0.50
SEMAGLUTIDE	associated_with	drug	0.50
FDG-PET	associated_with	biomarker	0.50
COMPLEMENT CASCADE	associated_with	pathway	0.50
SUBSTANTIA NIGRA	associated_with	brain_region	0.50
NLRP3 INFLAMMASOME	associated_with	pathway	0.50

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Elevated CSF/Serum Albumin Quotient Predicts Neurodegenerati	0.850	-	What blood-brain barrier permeability ch
CSF1R-TREM2 Co-Agonism for Sustained Microglial Expansion	0.808	neurodegeneration	TREM2 agonism vs antagonism in DAM micro
Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2,	0.807	biomarkers	What biomarkers can reliably detect micr
CSF sTREM2 as Pharmacodynamic Biomarker for Therapeutic Wind	0.801	neuroimmunology	TREM2 in Alzheimer's Disease: Mechanisms
TREM2-CSF1R Cross-Talk in Microglial Metabolic Reprogramming	0.748	neurodegeneration	Gene expression changes in aging mouse b

CSF YKL-40 as a Priming-Specific Chitinase Marker	0.723	biomarkers	What biomarkers can reliably detect micr
CSF/Plasma AQP4 Polarization Index as a Novel Biomarker of A	0.705	-	What blood-brain barrier permeability ch
CSF Soluble TREM2 Fragment Ratio as Priming State Indicator	0.689	biomarkers	What biomarkers can reliably detect micr
Matrix Metalloproteinase-9/TIMP-1 Ratio in CSF Identifies Pr	0.675	-	What blood-brain barrier permeability ch
CSF/Serum NfL Ratio Discriminates Active Transcytosis from P	0.665	-	What blood-brain barrier permeability ch
TREM2-Independent Microglial Activation via CSF1R	0.659	neurodegeneration	Methodology challenge: dataset 'Allen Br
CSF Biomarker-Guided ABCA7 Therapeutic Dosing	0.619	neurodegeneration	Why does the V1613M variant reduce amylo
CSF ApoE- and clusterin-rich lipoprotein particles stabilize	0.606	neurodegeneration	Which specific CSF molecular components
Temporal Decoupling of CSF p-tau217 Normalization from Amylo	0.595	neurodegeneration	-
CSF p-tau217 Normalization Reflects Amyloid-Driven Tau Patho	0.586	neurodegeneration	-
Residual Vascular Amyloid Prevents Complete CSF p-tau217 Nor	0.585	-	Can CSF p-tau217 normalization serve as
Ganglioside-rich extracellular vesicles preserve alpha-synuc	0.582	neurodegeneration	Which specific CSF molecular components
CSF1R Inhibition-Mediated Microglial Replacement as a State	0.581	neurodegeneration	How do different microglial subtypes (DA
CSF p-tau217 Normalization Occurs Earlier Than Amyloid PET N	0.565	-	Can CSF p-tau217 normalization serve as
CSF1R Partial Agonism Combined with TREM2 Activation for ALS	0.535	neurodegeneration	Microglial subtypes in neurodegeneration
Lactate/Pyruvate Ratio Dynamics in CSF as a Neuroinflammatio	0.532	translational-neuroscience	Which metabolic biomarkers can distingui
CSF p-tau217 Normalization Requires Intact Synaptic Function	0.515	neurodegeneration	-
CSF p-tau217 Threshold of <0.15 pg/mL Predicts Durable Clini	0.512	neurodegeneration	-
TREM2 on Perivascular Macrophages Senses Aβ and Drives SPP1	0.496	neurodegeneration	How do perivascular cells specifically r
Sulfated glycans and metal-binding CSF proteins brace alpha-	0.489	neurodegeneration	Which specific CSF molecular components
Amyloid Plaque Clearance Triggers Downstream Reduction in Ta	0.475	-	Can CSF p-tau217 normalization serve as
CSF Neurofilament Light Chain-Guided Astrocyte-Derived Extra	0.458	molecular-neurobiology	How does lncRNA-0021 achieve sequence-sp
CSF Neurofilament Light-Triggered Astrocyte-Derived Exosome	0.450	molecular-neurobiology	How does lncRNA-0021 achieve sequence-sp
CSF1R Agonism for TREM2-Independent Microglial Activation in	0.445	neurodegeneration	Test
CSF1R Inhibition Reversal Window Depends on Microglia Replac	0.395	neurodegeneration	What is the optimal therapeutic window f

Mentioning Analyses (11)

Scientific analyses that reference this entity

Microglial Priming as Upstream Causal Node Across AD, PD, ALS, MS: Three-Arm Cau

neurodegeneration | 2026-04-27 | 3 hypotheses Top: 0.604

Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determ

neurodegeneration | 2026-04-26 | 7 hypotheses Top: 0.585

What blood-brain barrier permeability changes serve as early biomarkers for neur

neurodegeneration | 2026-04-26 | 8 hypotheses Top: 0.940

What blood-brain barrier permeability changes serve as early biomarkers for neur

neurodegeneration | 2026-04-26 | 8 hypotheses Top: 0.745

Blood-brain barrier permeability changes as early biomarkers for neurodegenerati

neurodegeneration | 2026-04-26 | 3 hypotheses Top: 0.362

Experiments (1)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Autophagy receptor identification for stress granule elimination	exploratory	neurodegenerative diseases	0.900	0.00	cultured cells under arsenite	proposed	N/A

Related Papers (8)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025
Neurodegeneration and demyelination in multiple sclerosis. [PMID:38889714]	Garton T, Gadani SP, Gill AJ, Calabresi	Neuron	2024
STING orchestrates the neuronal inflammatory stress response in multiple scleros [PMID:38878778]	Woo MS, Mayer C, Binkle-Ladisch L, Sonne	Cell	2024
Gasdermin-E mediates mitochondrial damage in axons and neurodegeneration. [PMID:36917977]	Neel DV, Basu H, Gunner G, Bergstresser	Neuron	2023
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disea [PMID:33182554]	Marogianni C, Sokratous M, Dardiotis E,	International journal of molec	2020
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disea [PMID:33182554]	Marogianni C, Sokratous M, Dardiotis E,	International journal of molec	2020
Multiple Sclerosis Pathology. [PMID:29358320]	Lassmann H	Cold Spring Harbor perspective	2018

Debates (15)

Multi-agent debates referencing this entity

Is microglial priming (TREM2/CX3CR1/complement-C1q) genuinely causally upstream

closed · Rounds: 4 · Score: 0.64 · 2026-04-28

What is the evidence that blood-brain barrier (BBB) permeability changes serve a

closed · Rounds: 4 · Score: 1.00 · 2026-04-26

Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determ

closed · Rounds: 4 · Score: 1.00 · 2026-04-26

Formal debate: plasma GFAP separates causal from compensatory states in: Blood-b

closed · Rounds: 3 · Score: 0.75 · 2026-04-26

Formal debate: tight-junction remodeling is the actionable driver in: Blood-brai

closed · Rounds: 3 · Score: 0.75 · 2026-04-26

What blood-brain barrier permeability changes serve as early biomarkers for neur

closed · Rounds: 4 · Score: 1.00 · 2026-04-26

What blood-brain barrier permeability changes serve as early biomarkers for neur

closed · Rounds: 4 · Score: 1.00 · 2026-04-26

Blood-brain barrier permeability changes as early biomarkers for neurodegenerati

closed · Rounds: 4 · Score: 0.78 · 2026-04-26

Blood-brain barrier permeability changes as early biomarkers for neurodegenerati

closed · Rounds: 7 · Score: 0.50 · 2026-04-26

Which specific CSF molecular components are essential for maintaining disease-re

closed · Rounds: 4 · Score: 0.66 · 2026-04-25

Related Research

Hypotheses and analyses mentioning CSF in their description or question text

CSF YKL-40 as a Priming-Specific Chitinase Marker

Score: 0.723 · biomarkers · 2026-04-22

## Mechanistic Overview CSF YKL-40 as a Priming-Specific Chitinase Marker starts from the claim that modulating CHI3L1/Y

CSF/Plasma AQP4 Polarization Index as a Novel Biomarker of Astrocyte Glymphatic

Score: 0.705 · unknown disease · 2026-04-26

Aquaporin-4 (AQP4) water channels are normally concentrated at astrocyte end-feet ensheathing cerebral microvessels. Ear

CSF Soluble TREM2 Fragment Ratio as Priming State Indicator

Score: 0.689 · biomarkers · 2026-04-22

## Mechanistic Overview CSF Soluble TREM2 Fragment Ratio as Priming State Indicator starts from the claim that modulatin

Matrix Metalloproteinase-9/TIMP-1 Ratio in CSF Identifies Preclinical Tight Junc

Score: 0.675 · unknown disease · 2026-04-26

Matrix metalloproteinase-9 (MMP-9) degrades tight junction proteins (claudin-5, occludin, ZO-1) and extracellular matrix

CSF/Serum NfL Ratio Discriminates Active Transcytosis from Passive BBB Breakdown

Score: 0.665 · unknown disease · 2026-04-26

Neurofilament light chain (NfL) released from damaged neurons requires crossing the BBB to appear in blood. Two mechanis

TREM2-Independent Microglial Activation via CSF1R

Score: 0.659 · neurodegeneration · 2026-04-28

Identification of a TREM2-independent disease-associated microglial (DAM) trajectory in late-stage AD. Single-cell analy

CSF Biomarker-Guided ABCA7 Therapeutic Dosing

Score: 0.619 · neurodegeneration · 2026-04-14

## **Molecular Mechanism and Rationale** ABCA7 (ATP-binding cassette transporter A7) functions as a critical lipid effl

CSF ApoE- and clusterin-rich lipoprotein particles stabilize disease-relevant al

Score: 0.606 · neurodegeneration · 2026-04-25

Specific lipoprotein particles bind fibril surfaces and preserve polymorph architecture and seeding fidelity outside the

Residual Vascular Amyloid Prevents Complete CSF p-tau217 Normalization, Requirin

Score: 0.585 · unknown disease · 2026-04-26

Cerebral amyloid angiopathy (CAA) maintains a reservoir of vascular amyloid that continues to drive tau pathology even a

Ganglioside-rich extracellular vesicles preserve alpha-synuclein fibril conforma

Score: 0.582 · neurodegeneration · 2026-04-25

Membrane-derived cofactors in extracellular vesicles maintain polymorph fidelity and templating competence.

CSF1R Inhibition-Mediated Microglial Replacement as a State Transition Reset

Score: 0.581 · neurodegeneration · 2026-04-16

## Mechanistic Overview CSF1R Inhibition-Mediated Microglial Replacement as a State Transition Reset starts from the cla

CSF p-tau217 Normalization Occurs Earlier Than Amyloid PET Negativity, Enabling

Score: 0.565 · unknown disease · 2026-04-26

CSF p-tau217 normalizes before amyloid PET reaches cessation thresholds because p-tau217 reflects active neuronal pathol

CSF1R Partial Agonism Combined with TREM2 Activation for ALS Neuroprotection

Score: 0.535 · neurodegeneration · 2026-04-25

Premature investment. The Expert identifies that no validated partial CSF1R agonist exists—creating partial agonism for

CSF

Understanding Entity Pages

Wiki Pages (21)

CSF Neurofilament Light Chain (NfL) in Neurodegeneration

Validated Hypothesis: CSF1R-TREM2 Co-Agonism for Sustained Microglial Expansion

Cerebrospinal Fluid (CSF) Biomarkers Overview

Validated Hypothesis: Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2, and Neurogranin

Validated Hypothesis: CSF sTREM2 as Pharmacodynamic Biomarker for Therapeutic Window Identification

Cerebrospinal Fluid (CSF) Biomarkers in Neurodegeneration

CSF1R Inhibitors for Parkinson's Disease

CSF-1R Inhibitors

NPTX1 and NPTXR CSF Markers Predict Alzheimer's Disease Progression

Microglial Proteins in CSF Reveal AD Progression States

CSF Biomarkers for Corticobasal Syndrome and Progressive Supranuclear Palsy

Glymphatic and CSF Dynamics Enhancement for CBS/PSP

CSF Dynamics and Glymphatic Therapy in CBS/PSP

CSF1R-Targeted Microglia Therapy

GM-CSF Sargramostim Phase 2 (NCT04902703) - AD Immunotherapy

Pexidartinib (PLX3397) CSF1R Inhibitor Parkinson's Disease Trial (NCT04888966)

CSF1R Modulation Therapy: Microglia Reset Protocol

Bruce L. Miller — Director of UCSF Memory and Aging Center

CSF1R Inhibitors for Neurodegeneration

CSF2RA — Colony Stimulating Factor 2 Receptor Alpha Chain

CSF O-GlcNAc — Target Engagement Biomarker for OGA Inhibitors

Pathway Diagram

Outgoing (58)

Incoming (76)

Targeting Hypotheses (30)

Mentioning Analyses (11)

Microglial Priming as Upstream Causal Node Across AD, PD, ALS, MS: Three-Arm Cau

Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determ

What blood-brain barrier permeability changes serve as early biomarkers for neur

What blood-brain barrier permeability changes serve as early biomarkers for neur

Blood-brain barrier permeability changes as early biomarkers for neurodegenerati

Blood-brain barrier permeability changes as early biomarkers for neurodegenerati

Which specific CSF molecular components are essential for maintaining disease-re

Proteomics Differential Expression in AD CSF and Brain Tissue

Metabolomic signatures of neurodegeneration: metabolic reprogramming in aging br

Neuroinflammation and microglial priming in early Alzheimer's Disease

Extracellular vesicle biomarkers for early AD detection

Experiments (1)

Related Papers (8)

Debates (15)

Is microglial priming (TREM2/CX3CR1/complement-C1q) genuinely causally upstream

What is the evidence that blood-brain barrier (BBB) permeability changes serve a

Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determ

Formal debate: plasma GFAP separates causal from compensatory states in: Blood-b

Formal debate: tight-junction remodeling is the actionable driver in: Blood-brai

What blood-brain barrier permeability changes serve as early biomarkers for neur

What blood-brain barrier permeability changes serve as early biomarkers for neur

Blood-brain barrier permeability changes as early biomarkers for neurodegenerati

Blood-brain barrier permeability changes as early biomarkers for neurodegenerati

Which specific CSF molecular components are essential for maintaining disease-re

Related Research

CSF YKL-40 as a Priming-Specific Chitinase Marker

CSF/Plasma AQP4 Polarization Index as a Novel Biomarker of Astrocyte Glymphatic

CSF Soluble TREM2 Fragment Ratio as Priming State Indicator

Matrix Metalloproteinase-9/TIMP-1 Ratio in CSF Identifies Preclinical Tight Junc

CSF/Serum NfL Ratio Discriminates Active Transcytosis from Passive BBB Breakdown

TREM2-Independent Microglial Activation via CSF1R

CSF Biomarker-Guided ABCA7 Therapeutic Dosing

CSF ApoE- and clusterin-rich lipoprotein particles stabilize disease-relevant al

Residual Vascular Amyloid Prevents Complete CSF p-tau217 Normalization, Requirin

Ganglioside-rich extracellular vesicles preserve alpha-synuclein fibril conforma

CSF1R Inhibition-Mediated Microglial Replacement as a State Transition Reset

CSF p-tau217 Normalization Occurs Earlier Than Amyloid PET Negativity, Enabling

CSF1R Partial Agonism Combined with TREM2 Activation for ALS Neuroprotection